by
Thomas Dworetzky, Contributing Reporter | February 19, 2016
Data and insights from Truven inform benefit decisions for one in three Americans, according to IBM. This sort of analysis is of major importance as the U.S. health system shifts to outcome-based payment and away from fee-for-service.
“Data is important,” health care IT industry veteran Todd Cozzens, managing director of Leerink Capital Partners,
told Crain's business. According to Cozzens, the lynchpin of matching patients' outcomes to disease, treatments and co-morbidities is the the matching of claims and clinical data. These data are available through just a few firms: Truven, Health Catalyst, Cerner or Epic.
Ad Statistics
Times Displayed: 109208
Times Visited: 6638 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
“It's a race for who can come up with the most valuable data. That is the future of health care – what are the most effective drugs, care paths and what combination of therapies work best,” said Cozzens.
The deal will add over 5,000 employees to IBM's roster. "The Truven Health Analytics team is eager to combine our capabilities and expertise with the Watson Health portfolio," Mike Boswood, president and CEO, Truven Health Analytics, said in a statement, adding that the deal should "help catapult the industry forward to transform health care and to save and improve lives."
The deal is slated to close later in 2016, once it satisfies closing conditions and passes regulatory reviews.
Back to HCB News
